


Diagnosis and Management of Gastroparesis




Case 1: 20 year old male

Case 1: 20 year old male

- Presents as an outpatient after a hospital stay in the internal medicine ward for unclear transient periumbilical pain
- Intermittent episodes of periumbilical pain (1x/2M) and
- Recurrent progressive postprandial fullness and vomiting for 8M with weight loss (8-10 Kg).
- Fatigue, cannot play football any more like before
- Otherwise healthy
- Normal western diet, no alcohol, no smoking
- Family history: Parents emigrated from Kosovo, otherwise unremarkable
- Current medications: Paracetamol, Metamizol as needed

Case 1: 20 year old male



Case 1: 20 year old male

Name	Einheit	Referenz	Wert	FT4	pmol/L	12.2 - 23.5	18.5
▼ Blut: Elektrolyte				▼ Blut: Anämieparameter			
Natrium	mmol/L	136 - 145	141	Vitamin B12	pmol/L	keine Referenzwert	437
Kalium	mmol/L	3.5 - 4.5	3.9	Ferritin ECLIA	µg/L	20 - 250	121
Chlorid	mmol/L	98 - 107	103	▼ Blut: Diabetesparameter			
Calcium gesamt	mmol/L	2.15 - 2.50	2.29	HbA1c (DCCT/NGSP)	%	4.8-5.9	5.3
Calcium korrigiert	mmol/L		2.24	HbA1c (IFCC)	mmol/mol	22 - 42	34
Anorg. Phosphat	mmol/L	0.81 - 1.45	1.09	▼ Blut: Erythrocytenparameter			
Magnesium	mmol/L	0.70 - 0.91	0.85	Erythrozyten-Folsäure	nmol/L	1008 - 2426	798 -
▼ Blut: Metabolite				▼ Hämatogramm			
Glucose	mmol/L	4.11 - 5.89	4.99	Entnahmeart			venös
Creatinin (P)	µmol/L	59 - 104	76	Leukozyten	G/L	3.00 - 10.5	8.67
eGFR nach CKD-EPI	mL/min	> 59	> 90	Hämoglobin	g/L	135 - 168	144
Harnstoff	mmol/L	3.2 - 7.3	3.2	Hämatokrit	L/L	0.40 - 0.50	0.40
Protein total	g/L	64 - 83	78	Erythrozyten	T/L	4.20 - 5.70	4.80
Albumin	g/L	35 - 52	42	MCV	fL	80 - 98	82
C-reaktives Protein	mg/L	< 5	< 3	MCH	pg	27 - 33	30
Bilirubin gesamt	µmol/L	< 17	4	MCHC	g/L	320 - 360	365 +
▼ Blut: Enzyme				RDW	%	11.5 - 14.5	11.9
ASAT	U/L	< 50	30	Thrombozyten	G/L	150 - 450	229
ALAT	U/L	< 50	51 +	MPV	fL	6.7 - 11.0	10.7
G-Glutamyltransferase	U/L	< 60	43	Normoblasten maschinell	/100 Leuk.	0	0.00
Lactat-Dehydrogenase	U/L	< 480	382	▼ Differenzierung maschinell			
Pankreas-Amylase	U/L	13 - 53	39	Neutrophile	G/L	1.60 - 7.40	5.27
▼ Blut: Schilddrüsenparameter				Eosinophile	G/L	0.02 - 0.40	0.08
TSH	mU/L	0.36 - 3.83	3.26	Basophile	G/L	0.00 - 0.15	0.10
FT4	pmol/L	12.2 - 23.5	18.5	Monozyten	G/L	0.20 - 0.93	0.71

Case 1: 20 year old male

- 21.08.2017 **Sonografie** Abdomen: keine akute Appendizitis, keine anderen Pathologien
- 09.11.2017 **Oesophago-Gastro-Duodenoskopie**: Normalbefund im oberen Gastrointestinaltrakt.
- 13.11.2017 Histopathologie Duodenal- und Magenschleimhaut:
keine histopathologischen Veränderungen. Keine chronische oder aktive Entzündung.
- 09.11.2017 **Helicobacter** pylori negativ.
- 24.11.2017 **Zöliakieabklärung**: Gliadin(DP)-Antikörper IgG und IgA negativ,
Antikörper gegen Transglutaminase IgA negativ.
- 21. und 23.01.2018 **Sonografie Abdomen**: keine intraabdominellen Pathologien
- 24.01.2018 **Laboruntersuchung und Urinstatus**: bland
- 24.01.2018 **CT Abdomen**: keine relevanten Pathologien
- 25.01.2018 Serologie: **Hepatitis B und C Virus HIV** negativ
- 26.01.2018 **Stuhlanalyse**: Nukleinsäuresequenz für allgemeine Enteritis Erreger negativ,
Mikroskopie ohne mikroskopisch nachgewiesenen Darmparasiten
- 26.01.2018 Urinuntersuchung auf **Porphyrrie**: keine Hinweise auf akute Porphyrrie
- 26.01.2018 **Sonografie** Abdomen: Keine Rektusdiastase. Keine Umbilikalhernie.
- 29.01.2018 **Koloskopie**: kein Korrelat für die Beschwerden des Patienten. Biopsate, Ileum und Kolonschleimhaut ohne histopathologische Veränderungen.
- 30.01.2018 **Toxikologisches Screening** Urin: unauffällig

Does the patient have a gastroparesis? Why/Why not?



Definition of Gastroparesis

The diagnosis of gastroparesis is based on the combination of

- symptoms of gastroparesis,
- absence of gastric outlet obstruction or ulceration, and
- delay in gastric emptying.



Symptoms of gastroparesis?



Symptoms of gastroparesis?

- **early satiety,**
- **postprandial fullness,**
- **nausea,**
- **vomiting,**
- *bloating,*
- *upper abdominal pain*

Do symptoms correlate with gastric emptying?

- **early satiety,**
- **postprandial fullness,**
- **nausea,**
- **vomiting,**
- *bloating,*
- *upper abdominal pain*


Case 1: 20 year old male

The diagnosis of gastroparesis is based on the combination of

- **symptoms of gastroparesis**
- **absence of gastric outlet obstruction or ulceration**
- **delay in gastric emptying.**


Normal gastrointestinal motor function

- Modulated through vagal (parasympathetic) and sympathetic stimuli, locally released transmitters and luminal input.
- Initiated by pacemaker cells (interstitial cells of Cajal)
- Spread to smooth muscle cells through the intrinsic (enteric) nervous system, which also serves as a communication network



INTERSTITIAL CELLS OF CAJAL (ICC)
ARE THE PACEMAKERS OF THE GUT


Slow waves are generated in
interstitial cells of Cajal



Koeppen & Stanton: Berne and Levy Physiology, 6th Edition.
Copyright © 2008 by Mosby, an imprint of Elsevier, Inc. All rights reserved

Normal gastrointestinal motor function

- Proximal stomach: changes in tone in response to eating,
- Distal stomach: max 3cpm phasic contractions that propagate to the pylorus



Do we need to measure gastric emptying?



Do we need to measure gastric emptying?

Of course!

- accelerated gastric emptying and functional dyspepsia can also present similarly
- Documentation of delayed gastric emptying is necessary before selecting therapy with prokinetics agents or GES.

*Tack J , Bisschops R , Sarnelli G . Pathophysiology and treatment of functional dyspepsia . *Gastroenterology* 2004 ; 127 : 1239 – 55 .

*Bredenoord AJ , Chial HJ , Camilleri M et al. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms . *Clin Gastroenterol Hepatol* 2003 ; 1 : 264 – 72 .



No! Not at this stage!





Figure 1. The relation between acceleration of gastric emptying and symptom improvement in gastroparesis patients after treatment with metoclopramide, domperidone, cisapride, erythromycin, botulinum toxin A (botox), and levosulpiride (11,16,22–26,13,35,43,46–54). A meta-regression analysis to evaluate the overall correlation between symptom improvement and GE resulted in a nonsignificant correlation ($P=0.4$).

Janssen P, Tack J et al. *Am J Gastroenterol.* 2013 Sep;108(9):1382-91



Let's take a closer look

***Tack J , Bisschops R , Sarnelli G .
Pathophysiology and treatment of functional
dyspepsia . Gastroenterology 2004 ; 127 : 1239 –
55 .**

Delayed gastric emptying is traditionally considered a major pathophysiologic mechanism underlying symptoms in functional dyspepsia and idiopathic gastroparesis.^{7,11,20–29} Several studies have investigated the relationship between delayed gastric emptying and symptom pattern and severity. Depending on the study, the percentage



Let's take a closer look

***Tack J , Bisschops R , Sarnelli G .
Pathophysiology and treatment of functional
dyspepsia . Gastroenterology 2004 ; 127 : 1239 –
55 .**

Most studies failed to find a convincing relationship between delayed gastric emptying and symptom pattern.^{20–22} More recently, 3 large-scale single-center studies showed that patients with delayed gastric emptying for solids are more likely to report postprandial fullness, nausea, and vomiting,^{7,11,28} although a large multicenter study failed to find any association²⁹ (Table 2). Almost all studies focused on solid emptying rate only. A recent large-scale study suggested an association between delayed emptying for liquids and symptoms of postprandial fullness.¹¹



Let's take a closer look

***Tack J , Bisschops R , Sarnelli G .
Pathophysiology and treatment of functional
dyspepsia . Gastroenterology 2004 ; 127 : 1239 –
55 .**

Furthermore, induction of delayed gastric emptying in healthy subjects by pharmacologic or dietary interventions is not associated with the occurrence of dyspeptic symptoms.⁸⁷ These observations question the relevance of delayed emptying as a mechanism underlying dyspeptic symptoms.



Let's take a closer look

***Bredenoord AJ , Chial HJ , Camilleri M et al.
Gastric accommodation and emptying in
evaluation of patients with upper gastrointestinal
symptoms . Clin Gastroenterol Hepatol **2003** ; 1 :
264 – 72**

- *Retrospective study on 214 patients that underwent SPECT to assess gastric accommodation and 4h scintigraphy*

No significant differences in the symptoms reported by patients with normal, accelerated, or delayed gastric emptying (Figure 4) were noted. Although the frequency of vomiting was 20% higher in the diabetics with delayed gastric emptying, this difference was not statistically significant (Figure 4).



Our data in 151 patients with functional dyspepsia (i.e., abnormal gastric accommodation in 46.7%) confirmed 3 smaller previous studies documenting that gastric accommodation was impaired in approximately 45% of patients evaluated using barostat^{3,12} or SPECT imaging.⁴ SPECT assisted the identification of a motor abnormality potentially contributing to symptoms in 26% of the functional dyspepsia patients who had normal gastric emptying. Thus, our data suggested that SPECT may provide additional insight into the pathophysiology of symptoms in this patient population. If more specific therapies are identified to correct the variety of pathophysiologic disturbances contributing to dyspepsia, these data suggest that the tests would help identify patients for selective and potentially more effective therapy.

Methods of measuring gastric emptying?



Methods of measuring gastric emptying?

- **Solid meal 4-hour gastric emptying scintigraphy**
 - Wireless motility capsule
 - C-13 breath testing
-
- Medications that affect gastric emptying should be stopped at least 48 h.
 - Hyperglycemia should be corrected before the test.

What about our method?



Gastric emptying T 1 / 2

Acceptable if

- imaging has been performed for 4 h or
 - at least to 50 % emptying
- *extrapolation to measure t 1 / 2 may be erroneous




Fig. 1 Fit of the function $y(t) = 1 - (1 - e^{-kt})^b$ to a typical solid emptying curve. Graph illustrates the two distinct portions of solid emptying, namely, the lag phase, as indicated by TLAG, and the emptying phase, which is characterised by the emptying rate, k .

Siegel JA et al. Biphasic nature of gastric emptying . Gut 1988 ; 29 : 85 – 9

Case 1: 20 year old male

- Gastric emptying study

Magenentleerungsmessung fest vom 14.12.2017

Klinische Angaben

1. Rezidivierende Ernesis unklarer Genese
 - Gastroskopie 11/2017: makroskopisch und histologisch unauffälliger Befund

Fragestellung

Gastroparese?

Untersucher: PD Dr. med. D. Pohl, Oberarzt m.e.V. (nicht anwesend)
L. Schnurre, Assistenzärztin (nicht anwesend)

Pflegefachpersonen: D. Jovanovic, MTA

Diagnose

1. Deutlich verzögerte Magenentleerung (fest)

Beurteilung und Procedere

Die gemessene Magenentleerung ist mit einer Halbwertszeit von 212 Minuten deutlich verzögert, womit wir den Verdacht auf eine Gastroparese bestätigen können.


Causes of secondary gastroparesis?




Causes of secondary gastroparesis

- Diabetes mellitus (30%)
- thyroid dysfunction
- neurological disease
- prior gastric or bariatric surgery (13%)
- autoimmune disorders

➤ **36% idiopathic**




How to diagnose autonomic dysfunction?



Plasma pancreatic polypeptide response to sham feeding

- **Controls and diabetic subjects without AN:** significant mean 60% increase
- **AN:** no significant hPP response occurred




Buysschaert M, Donckier J, et al. Diabetes 1985; 34:1181-1185.

Management of Gastroparesis, first steps?


General measures

- restoration of fluids and electrolytes
- nutritional support
- *(optimization of glycemic control)*



General measures

- restoration of fluids and electrolytes
- **nutritional support?**
- *(optimization of glycemic control)*




Nutritional Support

- Counseling from a dietician
- Frequent small volume meals
- Low in fat and soluble fiber.
- If unable to tolerate solid food, then use of homogenized or liquid nutrient meals is recommended.
- **If no oral intake -> NJS trial -> jejunostomy**
 - Loss > 10 % or more of the usual body weight during a period of 3 – 6 months
 - repeated hospitalizations for refractory symptoms.

Nutritional Support

Inappetenz. Diese Beschwerden stehen in keinem Zusammenhang mit bestimmten Nahrungsmitteln, mit fetthaltigen Speisen oder anderen Faktoren, welche die gastrale Motilität reduzieren würden. Unter der hochdosierten Energie- und Proteinsubstitution ist das Gewicht stabil, jedoch nicht zunehmend. Der Patient nimmt 3 Fresubin-Drinks (1900-2000 kcal) pro Tag ein. Bei

Pharmacologic therapy?




Pharmacologic therapy

- Metoclopramide = Domperidone




Pharmacologic therapy

- **Metoclopramide = Domperidone**
- **Erythromycin**
- **(Antiemetics)**
- **(TCAs)**



STW-5 (Iberogast)

- Relaxes Fundus and at the same time increases contractile waves in antrum
- Improves symptoms and motility
- 618 pat, UEGW 2018 (poster)
- Risks?



Hohenester B. et al. Neurogastroenterol Motil 2004;16:765-73

Prucalopride

	n	GEt1/2min*	SBTT(min)*	GC4hr*	GC24hr**	ACt1/2hr**
placebo	14	117±6	210±20	0.6±0.1	2.3±0.3	13.1±2.3
pruc 2mg	13	105±5	151±13**	1.0±0.2	2.5±0.2	10.0±2.1
pruc 4mg	11	92±5*	134±16*	1.6±0.2*	3.2±0.4*	6.8±2.1*

Gastric emptying after 7 days on prucalopride

Prucalopride significantly accelerates gastric, small bowel and ascending colon emptying in patients with FD or C-IBS.

Bouras EP, Camilleri M et al. Gastroenterology. 2001 Feb;120(2):354-60.

No response to medical therapy

konservative Therapien eingesetzt (diätetische Massnahmen, Primperan, Motilium, Erythromycin, Antiemetika) und bei komplett fehlendem Ansprechen wieder abgesetzt. Vor der Evaluation einer

Datum: 02.11.2018
Untersuchung: **Magenentleerungs- und Magenmotilitäts-Szintigraphie**
- Dynamische Aufnahmen des Magens während 40 min.
Radiodiagnostikum: 89 MBq Tc-99m-MAA in einer semisoliden Testmahlzeit

Quantitative Auswertung:

Eliminationshalbwertszeit	40.5 min. (Norm 20 ± 3 min.)
Kontraktionsfrequenz	3.43/min. (Norm 3 ± 1 /min.)
Kontraktionsamplitude	6.5% (Norm $28 \pm 8\%$)


Beurteilung:

1. Erheblich verlängerte Eliminationshalbwertszeit und somit Bild einer Gastroparese.
2. Reduzierte Kontraktionsamplitude und fehlenden Kontraktionsbanden (jedoch bei erhaltener Kontraktionsfrequenz) als möglicher Hinweis auf eine Motilitätsstörung.

Interventional therapies

- **G-POEM**

G-POEM



► **Fig. 1** Endoscopic views showing: **a** the submucosal bleb created by needle injection of the lifting solution (methylene blue and saline) 5 cm proximally to the pylorus; **b** a horizontal incision of 1–2 cm made at the 5- or 6-o'clock position to allow mucosal entry into the submucosal space; **c** submucosal tunneling performed with dissection of the submucosal fibers until the pyloric ring is seen; **d** the pyloric ring is seen at the end of the submucosal tunnel; **e** full-thickness myotomy is performed starting at the pylorus and proceeding proximally.

Kahaleh M et al. Endoscopy. 2018 Nov;50(11):1053-1058

► **Table 4** Previous studies of gastric peroral endoscopic pyloromyotomy reported in the literature.

Study	Total number of patients	Clinical success rates	Follow-up, months	Adverse event rate
Shlomovitz et al. [24]	7	85 % (symptom improvement); 80 % (normalization of GES)	6.5	14%
Khashab et al. [1]	30	86 % (symptom improvement); 47 % (normalization of GES)	5.5	6.7 %
Dacha et al. [25]	16	81 % (decrease in GCSI); 75 % (normalization of GES)	12	0%
Gonzalez et al. [3]	12	85 % (decrease in GCSI); 75 % (normalization of GES)	3	0%
Xue et al. [26]	14	61 % (decrease in GCSI); 83 % (decrease in GES)	2	0%

GES, gastric emptying scintigraphy; GCSI, gastroparesis cardinal symptoms index.

► **Table 3** Comparison of the primary outcomes before and after the gastric peroral endoscopic pyloromyotomy procedure.

	Preoperative	Postoperative	P value
Mean GCSI score	3.3	0.8	<0.001
Mean GES time, minutes	222.4	143.2	<0.001
Mean gastric retention at 2 hours, %	75.8	58.3	0.01
Mean gastric retention at 4 hours, %	45.0	29.6	0.04



GCSI, gastroparesis cardinal symptoms index; GES, gastric emptying scintigraphy.

Kahaleh M et al. Endoscopy. 2018 Nov;50(11):1053-1058

Interventional therapies

- **G-POEM**
- **Intrapyloric Botox-injection**

Intrapyloric Botox in patients with delayed gastric emptying



Arts J et al. Aliment Pharmacol Ther. 2007 Nov 1;26(9):1251-8.

Interventional therapies

- **G-POEM**
- **Intrapyloric Botox-injection**
- **Gastric electrical stimulation**

Gastric electrical stimulation

- > 20 Trials, only 3 RCTs (4th coming?)
- 2 negative, 1 partly positive
- Diabetic > idiopathic
- No effect on gastric emptying
- Nonresponse, infection, electrode dislocation lead to explantation in up to 10%

Interventional therapies

- **G-POEM**
- **Intrapyloric Botox-injection**
- **Gastric electrical stimulation**
- **Surgery**
 - **Feeding jejunostomy + venting Gastrostomy**
 - **(Gastrojejunostomy)**
 - **(Gastrectomy)**

Thank you for your attention